We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Non-Small Cell Lung Cancer
MedXY News
EnglishTag

Non-Small Cell Lung Cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Resection Extent in Non-Small Cell Lung Cancer: Margin Positivity is Unrelated to Surgical Scope
General SurgeryNon-Small Cell Lung Cancersurgical margins

Resection Extent in Non-Small Cell Lung Cancer: Margin Positivity is Unrelated to Surgical Scope

By MedXY|Aug 14, 2026

A recent study demonstrates that positive surgical margins in non-small cell lung cancer (NSCLC) do not vary significantly with resection type, supporting selective use of wedge resection without compromising oncologic outcomes.

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial
newsNon-Small Cell Lung Cancer
perioperative immunotherapy

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

By MedXY|Jul 20, 2026

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly en

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan
newsJapanNon-Small Cell Lung Cancer

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan

By MedXY|May 29, 2026

A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge
newsimmunotherapyNon-Small Cell Lung Cancer

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

By MedXY|Apr 14, 2026

A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.

Risk and Outcomes of Secondary Cancer Among Lung Cancer Survivors After Definitive Treatment: A Comprehensive Review
Clinical Updateslung cancerNon-Small Cell Lung Cancer

Risk and Outcomes of Secondary Cancer Among Lung Cancer Survivors After Definitive Treatment: A Comprehensive Review

By MedXY|Dec 13, 2025

This review synthesizes evidence on the incidence, risk factors, and outcomes of secondary cancers in non-small cell lung cancer survivors post-definitive therapy, highlighting genetic predisposition as a key determinant distinct from recur

Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes
Clinical UpdatesBRAF V600Eencorafenib

Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes

By MedXY|Dec 9, 2025

The Phase II PHAROS study demonstrates durable antitumor efficacy and manageable safety of encorafenib plus binimetinib in BRAF V600E-mutant metastatic NSCLC, with updated results showing the longest median overall survival reported for tar

Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C Results
newsamivantamablazertinib

Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C Results

By MedXY|Dec 8, 2025

In CHRYSALIS‑2 Cohort C, the amivantamab plus lazertinib combination produced a 52% ORR and durable responses (mDoR 14.1 months) in advanced NSCLC with atypical EGFR mutations, with higher activity in treatment‑naïve patients and an expecte

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial
newschemotherapymetastatic NSCLC

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

By MedXY|Oct 15, 2025

The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeut

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression
newschemotherapyNon-Small Cell Lung Cancer

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY|Oct 15, 2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety p

Optimizing Anesthesia in Elderly NSCLC Patients: Impact of Midazolam and Dexmedetomidine Co-Administration on Hemodynamics and Stress Response
Anesthesiologydexmedetomidinehemodynamics

Optimizing Anesthesia in Elderly NSCLC Patients: Impact of Midazolam and Dexmedetomidine Co-Administration on Hemodynamics and Stress Response

By MedXY|Oct 7, 2025

Co-administering midazolam with dexmedetomidine in elderly NSCLC patients undergoing lobectomy enhances hemodynamic stability and reduces perioperative stress response, potentially improving recovery outcomes without increasing adverse even

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy
Clinical UpdatesAntibody-drug conjugateHER3-DXd

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY|Oct 7, 2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial
newsDocetaxelKRASG12C

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial

By MedXY|Oct 3, 2025

The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities